Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3045% below fair value
$24.95+0.14 (+0.56%)
Close on Nov 12, 2026Market cap $812.26MP/E 24.9Yield –
Collegium Pharmaceutical r&d expenses
Research and development expenses are spending on new products and technology.
Collegium Pharmaceutical's R&D Expenses for the twelve months ending Dec 31, 2022 was $3.98M, down 57.9% year over year. For fiscal 2024 it was $0. The highest annual figure on record is $14.96M in fiscal 2014.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $3.98M | -57.9% |
| FY2021 | Dec 31, 2021 | $9.45M | -3.3% |
| FY2020 | Dec 31, 2020 | $9.77M | -5.5% |
| FY2019 | Dec 31, 2019 | $10.34M | +19.4% |
| FY2018 | Dec 31, 2018 | $8.66M | +1.0% |
| FY2017 | Dec 31, 2017 | $8.57M | -42.7% |
| FY2016 | Dec 31, 2016 | $14.95M | +87.4% |
| FY2015 | Dec 31, 2015 | $7.98M | -46.7% |
| FY2014 | Dec 31, 2014 | $14.96M | +5.7% |
| FY2013 | Dec 31, 2013 | $14.16M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022 | Jun 30, 2022 | $0 | -100.0% |
| Q1 FY2022 | Mar 31, 2022 | $0 | -100.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.61M | -34.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.45M | -32.3% |
| Q2 FY2021 | Jun 30, 2021 | $3.46M | +38.9% |
| Q1 FY2021 | Mar 31, 2021 | $2.93M | +9.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.47M | +3.1% |
| Q3 FY2020 | Sep 30, 2020 | $2.14M | -14.1% |
| Q2 FY2020 | Jun 30, 2020 | $2.49M | +1.4% |
| Q1 FY2020 | Mar 31, 2020 | $2.67M | -10.9% |
| Q4 FY2019 | Dec 31, 2019 | $2.40M | +6.6% |
| Q3 FY2019 | Sep 30, 2019 | $2.49M | +30.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.46M | +9.9% |
| Q1 FY2019 | Mar 31, 2019 | $2.99M | +31.9% |
| Q4 FY2018 | Dec 31, 2018 | $2.25M | +2.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.91M | -7.8% |
| Q2 FY2018 | Jun 30, 2018 | $2.24M | +2.7% |
| Q1 FY2018 | Mar 31, 2018 | $2.27M | +6.5% |
| Q4 FY2017 | Dec 31, 2017 | $2.19M | -34.1% |
| Q3 FY2017 | Sep 30, 2017 | $2.07M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.18M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.13M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.33M | – |
See a number that looks wrong?